Sort
23,748 grants matching “melanoma”
Microenvironment mediated drug resistance in melanoma.
$346,525Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2011 · CA
Microenvironment mediated drug resistance in melanoma.
$346,525Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2012 · CA
The B7x pathway in the tumor microenvironment
$346,525Xingxing Zang · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · CA
Designing Lymph Nodes for Cancer Immunotherapy
$346,525James J Mule · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2010 · CA
The B7x pathway in the tumor microenvironment
$346,525Xingxing Zang · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · CA
Treatment of Melanoma with Optimzed Peptide Vaccines
$346,525Esteban Celis · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2010 · CA
Microenvironment mediated drug resistance in melanoma.
$346,525Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2015 · CA
CANCER AND LEUKEMIA GROUP B
$346,521Sloan-Kettering Institute For Cancer Res · U10 · FY2003 · CA
CLASS II ANTIGEN PRESENTATION VIA CHAPERONE MEDIATED AUTOPHAGY
$346,500Janice S Blum · Indiana University Indianapolis · R01 · FY2010 · AI
Mechanical control of cell growth and differentiation
$346,500Paul A Janmey · University Of Pennsylvania · R01 · FY2008 · GM
Mechanical control of cell growth and differentiation
$346,500Paul A Janmey · University Of Pennsylvania · R01 · FY2009 · GM
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$346,493John Tanner Wilson · Vanderbilt University · R01 · FY2024 · CA
Erythropoietin receptor-driven tumor initiation and progression
$346,478Jin Mo Park · Massachusetts General Hospital · R01 · FY2017 · CA
Erythropoietin receptor-driven tumor initiation and progression
$346,478Jin Mo Park · Massachusetts General Hospital · R01 · FY2015 · CA
Erythropoietin receptor-driven tumor initiation and progression
$346,478Jin Mo Park · Massachusetts General Hospital · R01 · FY2016 · CA
Dendritic Cell-Based Genetic Immunotherapy for Melanoma
$346,478University Of California Los Angeles · R01 · FY2004 · CA
Erythropoietin receptor-driven tumor initiation and progression
$346,478Jin Mo Park · Massachusetts General Hospital · R01 · FY2014 · CA
Erythropoietin receptor-driven tumor initiation and progression
$346,478Jin Mo Park · Massachusetts General Hospital · R01 · FY2018 · CA
T4 Endonuclease V Structure-Function Analysis
$346,382R Stephen Lloyd · Oregon Health & Science University · R01 · FY2009 · ES
Treatment of Melanoma with Optimzed Peptide Vaccines
$346,352Esteban Celis · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2009 · CA
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
$346,320Bjoern F Lillemeier · Salk Institute For Biological Studies · R01 · FY2019 · GM
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
$346,320Ye Zheng · Salk Institute For Biological Studies · R01 · FY2020 · GM
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
$346,320Bjoern F Lillemeier · Salk Institute For Biological Studies · R01 · FY2018 · GM
Human engineered enzymes for L-Arg depletion chemotherapy
$346,306George Georgiou Georgiou · University Of Texas At Austin · R01 · FY2010 · CA
Novel Therapeutics Targeting INPP5A Pathway in Squamous Cell Carcinoma
$346,236Aleksandar None Sekulic · Mayo Clinic Arizona · R01 · FY2018 · CA